Integrated Wealth Concepts LLC Acquires 888 Shares of Zoetis Inc. $ZTS

Integrated Wealth Concepts LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,553 shares of the company’s stock after acquiring an additional 888 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Zoetis were worth $1,244,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ZTS. Nuveen LLC bought a new stake in shares of Zoetis during the 1st quarter valued at about $616,375,000. Sarasin & Partners LLP bought a new stake in Zoetis in the 1st quarter worth approximately $339,111,000. Mackenzie Financial Corp lifted its position in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC lifted its position in Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock worth $289,666,000 after buying an additional 1,747,423 shares during the last quarter. Finally, Polen Capital Management LLC lifted its position in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $149.45 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business’s 50 day simple moving average is $152.70 and its two-hundred day simple moving average is $157.56. The stock has a market capitalization of $66.24 billion, a P/E ratio of 25.72, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZTS shares. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.